Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep;30(9):7147-7157.
doi: 10.1007/s00520-022-07053-y. Epub 2022 Apr 23.

Quality of life of ovarian cancer patients treated with combined platinum taxane chemotherapy: a systematic review of the literature

Vasilios Pergialiotis  1   2 , Ioanna Myrto Sotiropoulou  3 , Efstathia Liatsou  3 , Michalis Liontos  4 , Maximos Frountzas  3 , Nikolaos Thomakos  5 , Alexandros Rodolakis  5 , Dimitrios Haidopoulos  5
Affiliations

Quality of life of ovarian cancer patients treated with combined platinum taxane chemotherapy: a systematic review of the literature

Vasilios Pergialiotis et al. Support Care Cancer. 2022 Sep.

Abstract

Purpose: Chemotherapy is the cornerstone of adjuvant therapy in ovarian cancer. Its impact on the quality of life (QoL) has been addressed in several studies; however, several misperceptions concerning this affect patient counseling and physicians' ability to overcome patient fears. In the present systematic review, we sought to accumulate current evidence in the field in order to help establish robust information that will help physicians answer patients' questions.

Methods: The present systematic review is based on the PRISMA guidelines. Studies that evaluated patient QoL pre-, during, and post-chemotherapy with the use of the QLQC-30 were selected for inclusion. Their methodological quality was assessed with the before-after studies tool that is proposed by the National Institute of Health (NIH).

Results: Ten studies that involved 5181 patients were included in the present systematic review. The risk of bias and methodological quality of included studies was of good and fair overall quality. Retrieved data suggest there is substantial evidence that points toward improved global QoL among ovarian cancer patients treated with taxanes-platinum combination therapy. Individual outcomes evaluated with the QLQ-C30 also provide positive results, although underreporting was noted.

Conclusion: Despite the significant heterogeneity in outcome reporting, the findings of this study reveal the significant benefit of combined platinum taxane chemotherapy on the QoL of ovarian cancer patients and can be used for patients counseling in order to reduce refusals that arise from fear of adverse effects that may negatively affect QoL. Graphical abstract.

Keywords: EORTC; Ovarian cancer; QLQ-C30; Quality of life; Systematic review.

PubMed Disclaimer

References

    1. Bezjak A, Tu D, Bacon M, Osoba D, Zee B, Stuart G, Roy JA, Piccart M, Eisenhauer E (2004) Quality of life in ovarian cancer patients: comparison of paclitaxel plus cisplatin, with cyclophosphamide plus cisplatin in a randomized study. J Clin Oncol 22:4595–4603. https://doi.org/10.1200/jco.2004.08.080 - DOI - PubMed
    1. Bhat G, Karakasis K, Oza AM (2020) Measuring quality of life in ovarian cancer clinical trials – can we improve objectivity and cross trial comparisons? Cancers (Basel) 12. https://doi.org/10.3390/cancers12113296
    1. Bhugwandass CS, Pijnenborg JM, Pijlman B, Ezendam NP (2016) Effect of chemotherapy on health-related quality of life among early-stage ovarian cancer survivors: a study from the population-based PROFILES registry. Curr Oncol 23:e556–e562. https://doi.org/10.3747/co.23.3243 - DOI - PubMed - PMC
    1. Blagden SP, Cook AD, Poole C, Howells L, McNeish IA, Dean A, Kim JW, O’Donnell DM, Hook J, James EC, White IR, Perren T, Lord R, Dark G, Earl HM, Hall M, Kaplan R, Ledermann JA, Clamp AR (2020) Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. Lancet Oncol 21:969–977. https://doi.org/10.1016/s1470-2045(20)30218-7 - DOI - PubMed - PMC
    1. Brotto L, Brundage M, Hoskins P, Vergote I, Cervantes A, Casado HA, Poveda A, Eisenhauer E, Tu D (2016) Randomized study of sequential cisplatin-topotecan/carboplatin-paclitaxel versus carboplatin-paclitaxel: effects on quality of life. Support Care Cancer 24:1241–1249. https://doi.org/10.1007/s00520-015-2873-8 - DOI - PubMed

Publication types

LinkOut - more resources